Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
David Mott Insider Profile
11 Followers
David Mott, Ten Percent Owner at Arca Biopharma, holds 598.29K shares in Mersana Therapeutics (Ticker: MRSN), holds 1.19M shares in Ardelyx (Ticker: ARDX), holds 43.80K shares in Novavax (Ticker: NVAX).
Profitable Transactions
22 out of 65 Profitable Transactions
Average Return
+10.80%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that David Mott holds in companies
Most Profitable Insider Trade
Stock:
Achaogen
(AKAOQ)
(AKAOQ)
Rating:Informative Buy
Date:Jun 07, 2016 - Jun 07, 2017
Return:+423.70%
The most profitable trade made by David Mott
David Mott's Trading History
Arca Biopharma
Feb 27, 2018
Ten Percent Owner
Informative Sell
730.10K
$0.00
Adaptimmune Therapeutics
Jan 28, 2020
Director
Informative Buy
4.95M
$116.83M
AVEO Pharma
Apr 08, 2019
―
Informative Buy
4.96M
$378.66M
Achaogen
Dec 19, 2016
―
Informative Buy
6.75M
$117.88K
Cascadian Therapeutics
Mar 13, 2018
―
Uninformative Sell
―
$0.00
Regulus
May 09, 2019
Ten Percent Owner
Informative Buy
1.23M
$4.64M
Appian
Feb 15, 2018
Ten Percent Owner
Uninformative Sell
―
$582.73K
Mersana Therapeutics
Jan 04, 2024
Director
Uninformative Buy
―
$1.92M
Synlogic
Jan 26, 2018
Ten Percent Owner
Uninformative Buy
4.00M
$8.08M
Surface Oncology
Apr 23, 2018
―
Informative Buy
2.00M
$3.54M
Mulesoft Inc
May 09, 2018
―
Uninformative Sell
―
$0.00
Elastic
Oct 10, 2018
Ten Percent Owner
Uninformative Buy
―
$651.49M
Nightstar Therapeutics Limited
Jun 07, 2019
―
Uninformative Sell
169.89M
$0.00
Genocea Biosciences
Jun 25, 2019
Ten Percent Owner
Informative Buy
10.00M
$108.39K
Trevi Therapeutics
May 13, 2019
Ten Percent Owner
Uninformative Buy
―
$12.65M
Mirum Pharmaceuticals
Jul 24, 2019
Ten Percent Owner
Uninformative Buy
―
$102.23M
Enliven Therapeutics
Feb 23, 2022
Director
Informative Buy
219.67K
$3.98M
Novavax
Jun 13, 2023
Director
Uninformative Buy
―
$183.52K
Ardelyx
Jun 16, 2023
Director
Uninformative Buy
―
$7.62M
TRACON Pharmaceuticals
Mar 27, 2018
Ten Percent Owner
Informative Buy
1.91M
$6.41M
Epizyme
Aug 16, 2022
―
Uninformative Sell
―
$0.00
Box
Jan 22, 2015
Ten Percent Owner
Informative Buy
―
$4.44M
Tesaro
Jan 22, 2019
―
Uninformative Sell
782.79M
$0.00
Dermira
Oct 08, 2014
―
Informative Buy
1.11M
$65.68M
Loxo Oncology
Aug 06, 2014
―
Informative Buy
3.00M
$419.91M
Aerohive Networks
Apr 03, 2014
―
Uninformative Buy
―
$20.75M
Care
Nov 08, 2017
―
Uninformative Sell
―
$33.88M
Millennial Media
Oct 30, 2012
―
Informative Sell
21.47M
$14.34M
Sorrento Tech Inc
Jul 22, 2014
―
Informative Buy
4.60M
$2.09M
Workday
Apr 11, 2013
Ten Percent Owner
Uninformative Buy
―
$300.74K
Clovis Oncology
Jun 05, 2013
―
Uninformative Buy
―
$8.63
Omthera
―
―
―
―
List of latest transactions for each holding click on a transaction to see David Mott's performance on stock
You May Also Like
David Mott insider profile FAQ
What is the percentage of profitable transactions made by David Mott?
The percentage of profitable transactions made by David Mott is 34%.
What is the average return per transaction made by David Mott?
The average return per transaction made by David Mott is 10.80%.
What stocks does David Mott hold?
David Mott holds: ABIO, ADAP, AVEO, AKAOQ, CASC, RGLS, APPN, MRSN, SYBX, SURF, MULE, ESTC, NITE, GNCAQ, TRVI, MIRM, ELVN, NVAX, ARDX, TCON, EPZM, BOX, TSRO, ~DERM, LOXO, ~HIVE, CRCM, MM, ROKA, WDAY, CLVSQ, OMTH stocks.
What was David Mott’s latest transaction?
David Mott latest transaction was an Uninformative Buy of ―.
What was David Mott's most profitable transaction?
David Mott’s most profitable transaction was an Informative Buy of AKAOQ stock on June 7, 2016. The return on the trade was 423.70%.
What is David Mott's role in Arca Biopharma?
David Mott's role in Arca Biopharma is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.